Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | CCR4 | P51679 | 1/20 | 0.32 |
| ▸ | TNF | P01375 | 1/20 | 0.31 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL424668 | 0.72 | CYP1A2 (0.41) | ADORA2AADORA1DYRK1A | |
| SCHEMBL16976848 | 0.72 | DYRK1A (0.32) | DYRK1A | |
| SCHEMBL18937629 | 0.72 | CCR4 (0.33) | CCR4DYRK1A | |
| SCHEMBL24037449 | 0.69 | CCR4 (0.33) | CCR4 | |
| SCHEMBL22990772 | 0.69 | NCF1 (0.45) | ADORA2AADORA1CA2DYRK1A | |
| SCHEMBL7708390 | 0.69 | ADORA3 (0.36) | ADORA2AADORA1DYRK1A | |
| SCHEMBL22430450 | 0.69 | ADORA2A (0.50) | ADORA2AADORA1 | |
| SCHEMBL2811269 | 0.68 | AXL (0.36) | ADORA2AADORA1DYRK1A | |
| SCHEMBL29480807 | 0.68 | AXL (0.36) | ADORA2AADORA1DYRK1A | |
| SCHEMBL5174321 | 0.68 | DYRK1A (0.32) | DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814379-B2 | Cyano quinoline amide compounds as HER2 inhibitors and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230265107-A1 | PB2 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2023-08-24 | — | — | US | disclosed |
| US-20230265107-A1 | PB2 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2023-08-24 | — | — | US | disclosed |
| US-20210355119-A1 | CYANO QUINOLINE AMIDE COMPOUNDS AS HER2 INHIBITORS AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. | 2021-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11814379-B2 | Cyano quinoline amide compounds as HER2 inhibitors and methods of use | ERBB2, EGFR, ERBB3 | ADORA2A 3174/4885ADORA1 3289/4885CCR4 4551/4885 |
| US-20230265107-A1 | PB2 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | CYP11B2, WEE2, CYP11B1 | ADORA2A 4009/4885ADORA1 2261/4885CCR4 3801/4885 |
| US-20210355119-A1 | CYANO QUINOLINE AMIDE COMPOUNDS AS HER2 INHIBITORS AND METHODS OF USE | ERBB2, EGFR, ERBB3 | ADORA2A 3198/4885ADORA1 3333/4885CCR4 4613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.